[ad_1]
GOTHENBURG, SE / ACCESSWIRE / November 24, 2022 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 24, 2022 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical firm discovering and growing novel therapies for essentially the most troublesome signs of Parkinson’s illness, at the moment introduced that the corporate will current and take part at Redeye Life Science Day 2022 on Thursday, November 24, 2022.
Richard Godfrey, CEO, will take part in an interview phase at 11:40 CET on Thursday, November 24, 2022. A pre-recorded firm presentation is out there by way of the occasion platform. Comply with the dwell broadcast at https://www.redeye.se/occasions/850947/redeye-life-science-day.
A recording of the interview and presentation will probably be made obtainable on our firm web site, www.irlab.se, following the occasion.
For extra data:
Richard Godfrey, CEO
Telephone: +46 730 70 69 00
E-mail: [email protected]
About IRLAB
IRLAB discovers and develops novel therapies of Parkinson’s illness and different CNS problems. The corporate’s most superior drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Part IIb and are designed to deal with a few of the most tough signs associated to Parkinson’s . In 2021, Ipsen, a specialty pharma firm, acquired unique international rights to the event and commercialization of mesdopetam.
IRLAB has found and generated all its drug candidates and continues to find modern drug candidates for the therapy of CNS problems via its proprietary techniques biology-based Integrative Screening Course of (ISP) analysis platform. Along with IRLAB’s sturdy scientific pipeline, the corporate can also be progressing two preclinical applications, IRL942 and IRL757, in the direction of Part I research. IRLAB is listed on Nasdaq Stockholm. Extra data on www.irlab.se.
Attachments
IRLAB to current at Redeye Life Science Day 2022
SOURCE: IRLAB Therapeutics
View supply model on accesswire.com:
https://www.accesswire.com/728199/IRLAB-to-present-at-Redeye-Life-Science-Day-2022
[ad_2]
Source link
